Volume 4.27 | Jul 12

Mammary Cell News 4.27 July 12, 2012
Mammary Cell News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Metastasis and chemoresistance in cancer are linked phenomena, but the molecular basis for this link is unknown. Scientists uncovered a network of paracrine signals between carcinoma, myeloid, and endothelial cells that drives both processes in breast cancer. [Cell] Abstract

PneumaCult™-ALI Medium for Bronchial Epithelial Cells: Watch the Video
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Acetylation-Dependent Regulation of Skp2 Function
Although the underlying molecular mechanisms remain elusive, cytoplasmic Skp2 correlates with more aggressive forms of breast and prostate cancers. Scientists identified an acetylation-dependent regulatory mechanism governing Skp2 oncogenic function and provide insight into how cytoplasmic Skp2 controls cellular migration. [Cell] Abstract

Plasminogen Activator Inhibitor 1 – Insulin-Like Growth Factor Binding Protein 3 Cascade Regulates Stress-Induced Senescence
By using a secretome proteomics approach, scientists identified insulin-like growth factor binding protein 3 as a secreted mediator of breast cancer senescence upon chemotherapeutic drug treatment. [Proc Natl Acad Sci USA] Abstract | Press Release

Concomitant Targeting of Tumor Cells and Induction of T Cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
Scientists report that concurrent targeting of tumor cells and activation of T cells in the tumor microenvironment results in a synergistic inhibitory effect on tumor growth and overcomes resistance in two distinct PTEN-loss-mediated trastuzumab-resistant mammary tumor mouse models. [Cancer Res] Abstract

Germline Mutation of Brca1 Alters the Fate of Mammary Luminal Cells and Causes Luminal-to-Basal Mammary Tumor Transformation
Scientists report that germline mutation of Brca1 in p18-deficient mice blocks the increase of luminal progenitor cells, impairs luminal gene expression and promotes malignant transformation of mammary tumors. [Oncogene] Abstract

Regulation of DCIS to Invasive Breast Cancer Progression by Singleminded-2s (SIM2s)
To test the hypothesis that SIM2s regulates tumor cell differentiation, researchers analyzed SIM2s expression in human primary breast ductal carcinoma in situ (DCIS) samples and found that SIM2s is lost with progression from DCIS to invasive ductal cancer. [Oncogene] Abstract

The Scaffold Protein MEK Partner 1 Is Required for the Survival of Estrogen Receptor Positive Breast Cancer Cells
Scientists demonstrated a requirement for MEK partner 1 expression in estrogen receptor positive breast cancer cells. [Cell Commun Signal] Abstract | Full Article

Site-Specific CpG Methylation in the CCAAT/Enhancer Binding Protein Delta (CEBPδ) CpG Island in Breast Cancer Is Associated with Metastatic Relapse
Scientists analyzed the expression of CEBPδ and the methylation status of the CpG island in human breast cancer cell lines, 107 archival cases of primary breast cancer, and two series of metastatic breast cancers using qPCR and pyrosequencing. [Br J Cancer] Abstract | Press Release

HGFK1 Inhibits Bone Metastasis in Breast Cancer through the TAK1/p38 MAPK Signaling Pathway
Researchers showed, for the first time, that the kringle 1 domain of human hepatocyte growth factor (HGFK1) significantly inhibits the metastasis of breast cancer to bone by activating the TAK1/p38 mitogen-activated protein kinase (MAPK) signaling pathway and inhibiting receptor activator of nuclear factor-κB expression. [Cancer Gene Ther] Abstract

CLINICAL RESEARCH

Topical Toll-Like Receptor 7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer
Scientists evaluated the local tumor response rate of breast cancer skin metastases treated with topical imiquimod, applied five days/week for eight weeks. [Clin Cancer Res] Abstract

A Phase II Trial to Assess Efficacy and Safety of Afatinib in Extensively Pretreated Patients with HER2-Negative Metastatic Breast Cancer
This multicenter phase II study enrolled patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer progressing following no more than three lines of chemotherapy. [Breast Cancer Res Treat] Abstract

[Free Webinar] ALDH+ Cancer Precursor Cells in Drug Response Prediction - Watch Now.

INDUSTRY NEWS

HTG Molecular Diagnostics Licenses Breast Cancer Marker Patent Portfolio from Merck
HTG Molecular Diagnostics has been granted a non-exclusive license to develop, manufacture, and commercialize breast cancer diagnostic tests under Merck’s patent portfolio. [Marketwire] Press Release

CRT and ADC Therapeutics Join Forces on Antibody Drug Conjugates
Cancer Research Technology (CRT) and Switzerland-based ADC Therapeutics Sarl announced that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT’s ‘warhead’ and linker chemistries. [Cancer Research Technology]
Press Release

Eisai Announces Preliminary Results of Phase III Study (Study 301) of Anticancer Agent Halaven® versus Capecitabine in Locally Advanced or Metastatic Breast Cancer
Eisai Co., Ltd. announced preliminary results from Study 301 of its developed anticancer agent Halaven® versus capecitabine in women with locally advanced or metastatic breast cancer for whom prior treatment with both an anthracycline and taxane has failed. [Eisai Co., Ltd.] Press Release

Cancer Therapeutics CRC Presents Data on Second Targeted Drug for Cancer
Cancer Therapeutics announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening platform for the identification of small molecule inhibitors of protein ubiquitination. [Cancer Therapeutics CRC] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW California Breast Cancer Research Program Symposium: From Research to Action – Two Decades of Change
May 17-18, 2013
Orange County, United States

Visit
our events page to see a complete list of events in the mammary cell community.

JOB OPPORTUNITIES

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)


Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)


Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)


Postdoctoral Position – Gene Regulation in Breast Cancer/Stem Cell Biology (University of Cincinnati)

Assistant Professor – Oncology/Breast Cancer (University of Chicago)

Associate Professor – Metastatic Breast Cancer (University of Colorado Comprehensive Cancer Center)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us